USP53 Affects the Proliferation and Apoptosis of Breast Cancer Cells by Regulating the Ubiquitination Level of ZMYND11.

Autor: Meng, Xiangchao¹ (AUTHOR), Chen, Hongye² (AUTHOR), Tan, Zhihui¹ (AUTHOR), Yan, Weitao¹ (AUTHOR), Liu, Yinfeng¹ (AUTHOR), Lv, Ji¹ (AUTHOR) lvjiguoguo@139.com, Han, Meng¹ (AUTHOR) meng69527@139.com

Publikováno v: Biological Procedures Online. 7/23/2024, Vol. 26 Issue 1, p1-18. 18p.

USP53 Affects the Proliferation and Apoptosis of Breast Cancer Cells by Regulating the Ubiquitination Level of ZMYND11

Autor: Xiangchao Meng, Hongye Chen, Zhihui Tan, Weitao Yan, Yinfeng Liu, Ji Lv, Meng Han

Publikováno v: Biological Procedures Online, Vol 26, Iss 1, Pp 1-18 (2024)

Abstract Breast cancer is the most common female malignancy worldwide. Ubiquitin-specific peptidase 53 (USP53) has been shown to exert cancer-suppressing functions in several solid tumors, but its role and the underlying mechanism in breast cancer ha

Externí odkaz: https://doaj.org/article/abe30febad3341fdb4041ba389c1eb68

Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity

Autor: Cheng Lian, Chunyi Zhang, Pan Tian, Qilong Tan, Yu Wei, Zixian Wang, Qin Zhang, Qixiang Zhang, Mengjie Zhong, Li-Quan Zhou, Xisong Ke, Huabing Zhang, Yao Zhu, Zhenfei Li, Jingdong Cheng, Gong-Hong Wei

Publikováno v: Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-22 (2024)

Abstract Epigenetic readers frequently affect gene regulation, correlate with disease prognosis, and hold significant potential as therapeutic targets for cancer. Zinc finger MYND-type containing 11 (ZMYND11) is notably recognized for reading the epi

Externí odkaz: https://doaj.org/article/62d5d4c2a9d74c978df9588ca6d15d3f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Acute myeloid leukemia with a ZMYND11 :: MBTD1 fusion gene following chemotherapy and radiotherapy for breast cancer: A case report.

Autor: Kawai H; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.; Department of Hematology, Hiratsuka Mutual Aid Hospital, Hiratsuka, Kanagawa, Japan., Shiraiwa S; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Ogiya D; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Toyosaki M; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Machida S; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Suzuki R; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Onizuka M; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Ogawa Y; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Kawada H; Department of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

Publikováno v: Leukemia research reports [Leuk Res Rep] 2024 Aug 21; Vol. 22, pp. 100478. Date of Electronic Publication: 2024 Aug 21 (Print Publication: 2024).